3M™ Harvest RC Chromatographic Clarifier Beta Testing Series

<p>The global biologics market is expected to grow at a 10.8% compound annual growth rate (CAGR) leading up to 2028. COVID-19 vaccines and therapeutics will further drive this growth during the next 5 years. However, manufacturing monoclonal antibody therapies (mAbs) at a commercial scale is a costly, complex, and time-consuming process.</p> <p>The <a href="/doc/m-harvest-rc-single-stage-chromatographic-purification-for-recombinant-protein-therapeutic-manufacturing-0001" target="_blank">3M&trade; Harvest RC </a>is a new chromatographic Chinese hamster ovary (CHO) cell culture harvest product. It is a single-stage, single-use chromatographic purification solution for recombinant protein therapeutics manufacturing that replaces the centrifugation and depth filtration operations of the protein purification process.</p> <p>In this paper, professionals from pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and 3M Company, discussed the new 3M&trade; Harvest RC Chromatographic clarification technology following participation in a beta test program that allowed them early access to work with the product and provide hands-on feedback.</p>